Potent inhibition of human telomerase by nitrostyrene derivatives

Molecular Pharmacology

Volumn 63, Issue 5, 2003, Pages 1117-1124

  Kim, Joo Hee ^a   Kim, Jun Hyun ^a   Lee, Gun Eui ^a   Lee, Jong Eun ^a   Chung, In Kwon ^a  

^a Yonsei University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 NITROVINYL)NAPHTHALENE; 2,3 DICHLORONITROSTYRENE; 3 (3,5 DICHLOROPHENOXY)NITROSTYRENE; DNA POLYMERASE; NITRO DERIVATIVE; NITROSTYRENE DERIVATIVE; RNA DIRECTED DNA POLYMERASE; RNA POLYMERASE; STYRENE DERIVATIVE; TELOMERASE; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CANCER CELL CULTURE; DRUG BINDING; DRUG POTENCY; DRUG SCREENING; ENZYME INHIBITION; ENZYME KINETICS; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; SENESCENCE; TELOMERE;

CELL AGING; DNA-DIRECTED DNA POLYMERASE; DNA-DIRECTED RNA POLYMERASES; ENZYME INHIBITORS; HUMANS; PHENOTYPE; PHENYL ETHERS; STYRENES; TELOMERASE;

EID: 0038069024     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.63.5.1117     Document Type: Article

References (43)

1. Bearss DJ, Hurley LH, and Von Hoff DD (2000) Telomere maintenance mechanisms as a target for drug development. Oncogene 19:6632-6641.
2. Blackburn EH (1991) Structure and function of telomeres. Nature (Lond) 350:569-573.
3. Blackburn EH (1992) Telomerase. Annu Rev Biochem 61:113-129.
4. Blasco MA, Lee HW, Hande MP, Samper E, Lansdorp PM, DePinho RA, and Greider CW (1997) Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 91:25-34.
5. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, Harley CB, Shay JW, Lichtsteiner S, and Wright WE (1998) Extension of life-span by introduction of telomerase into normal human cells. Science (Wash DC) 279:349-352.
6. Brandon PC (1971) Inhibition of photophosphorylation by beta-bromo-beta-nitrostyrene. FEBS Lett 14:153-156.
7. Bryan TM, Englezou A, Dalla-Pozza L, Dunham MA, and Reddel RR (1997) Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med 3:1271-1274.
8. Bryan TM, Englezou A, Gupta J, Bacchetti S, and Reddel RR (1995) Telomere elongation in immortal human cells without detectable telomerase activity. EMBO (Eur Mol Biol Organ) J 14:4240-4248.
9. Carter KC, Finnon YS, Daeid NN, Robson DC, and Waddell R (2002) The effect of nitrostyrene on cell proliferation and macrophage immune responses. Immunopharmacol Immunotoxicol 24:187-197.
10. Corey DR (2002) Telomerase inhibition, oligonucleotides and clinical trials. Oncogene 21:631-637.
11. Counter CM, Avilion AA, LeFeuvre CE, Stewart NG, Greider CW, Harley CB, and Bacchetti S (1992) Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO (Eur Mol Biol Organ) J 11:1921-1929.
12. Damm K, Hemmann U, Garin-Chesa P, Hauel N, Kauffmann I, Priepke H, Niestroj C, Daiber C, Enenkel B, Guilliard B, et al. (2001) A highly selective telomerase inhibitor limiting human cancer cell proliferation. EMBO (Eur Mol Biol Organ) J 20:6958-6968.
13. Gowan SM, Harrison JR, Patterson L, Valenti M, Read MA, Neidle S, and Kelland LR (2002) A G-quadruplex-interactive potent small-molecule inhibitor of telomerase exhibiting in vitro and in vivo antitumor activity. Mol Pharmacol 61:1154-1162.
14. Gowan SM, Heald R, Stevens MF, and Kelland LR (2001) Potent inhibition of telomerase by small-molecule pentacyclic acridines capable of interacting with G-quadruplexes, Mol Pharmacol 60:981-988.
15. Grand CL, Han H, Munoz RM, Weitman S, Von Hoff DD, Hurley LH, and Bearss DJ (2002) The cationic porphyrin TMPyP4 down-regulates c-MYC and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo. Mol Cancer Ther 1:565-573.
16. Greider CW (1996) Telomere length regulation. Annu Rev Biochem 65:337-365.
17. Hahn WC, Stewart SA, Brooks MW, York SG, Eaton E, Kurachi A, Beijersbergen RL, Knoll JH, Meyerson M, and Weinberg RA (1999) Inhibition of telomerase limits the growth of human cancer cells. Nat Med 5:1164-1170.
18. Harley CB (1991) Telomere loss: mitotic clock or genetic time bomb? Mutat Res 256:271-282.
19. Harley CB, Futcher AB, and Greider CW (1990) Telomeres shorten during ageing of human fibroblasts. Nature (Lond) 345:458-460.
20. Harley CB, Kim NW, Prowse KR, Weinrich SL, Hirsch KS, West MD, Bacchetti S, Hirte HW, Counter CM, Greider CW, et al. (1994) Telomerase, cell immortality and cancer. Cold Spring Harb Symp Quant Biol 59:307-315.
21. Hastie ND, Dempster M, Dunlop MG, Thompson AM, Green DK, and Allshire RC (1990) Telomere reduction in human colorectal carcinoma and with ageing. Nature (Lond) 346:866-868.
22. Hayakawa N, Nozawa K, Ogawa A, Kato N, Yoshida K, Akamatsu K, Tsuchiya M, Nagasaka A, and Yoshida S (1999) Isothiazolone derivatives selectively inhibit telomerase from human and rat cancer cells in vitro. Biochemistry 38:11501-11507.
23. Herbert B, Pitts AE, Baker SI, Hamilton SE, Wright WE, Shay JW, and Corey DR (1999) Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proc Natl Acad Sci USA 96:14276-14281.
24. Hiyama E, Gollahon L, Kataoka T, Kuroi K, Yokoyama T, Gazdar AF, Hiyama K, Piatyszek MA, and Shay JW (1996) Telomerase activity in human breast tumors. J Natl Cancer Inst 88:116-122.
25. Izbicka E, Wheelhouse RT, Raymond E, Davidson KK, Lawrence RA, Sun D, Windle BE, Hurley LH, and Von Hoff DD (1999) Effects of cationic porphyrins as G-quadruplex interactive agents in human tumor cells. Cancer Res 59:639-644.
26. Kang MR and Chung IK (2002) Down-regulation of DNA topoisomerase IIα in human colorectal carcinoma cells resistant to a protoberberine alkaloid, berberrubine. Mol Pharmacol 61:879-884.
27. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PLC, Coviello GM, Wright WE, Weinrich SL, and Shay JW (1994) Specific association of human telomerase activity with immortal cells and cancer. Science (Wash DC) 266:2011-2015.
28. Kim NW and Wu F (1997) Advances in quantification and characterization of telomerase activity by the telomeric repeat amplification protocol (TRAP). Nucleic Acids Res 25:2595-2597.
29. Kiyono T, Foster SA, Koop JI, McDougall JK, Galloway DA, and Klingelhutz AJ (1998) Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature (Lond) 396:84-88.
30. Kondo Y, Koga S, Komata T, and Kondo S (2000) Treatment of prostate cancer in vitro and in vivo with 2-5A-anti-telomerase RNA component. Oncogene 19:2205-2211.
31. Lingner J, Cooper JP, and Cech TR (1995) Telomerase and DNA replication: no longer a lagging strand problem? Science (Wash DC) 269:1533-1534.
32. Mikami Y, Yazawa K, Maeda A, Uno J, Kubo A, Saito N, and Kawakami N (1991) Antifungal activity of SL-1, a beta-nitrostyrene type pigment and its synthetic congeners. J Antibiot (Tokyo) 44:1454-1456.
33. Naasani I, Seimiya H, Yamori T, and Tsuruo T (1999) FJ5002: a potent telomerase inhibitor identified by exploiting the disease-oriented screening program with COMPARE analysis. Cancer Res 59:4004-4011.
34. Pascolo E, Wenz C, Lingner J, Hauel N, Priepke H, Kauffmann I, Garin-Chesa P, Rettig WJ, Damm K, and Schnapp A (2002) Mechanism of human telomerase inhibition by BIBR1532, a synthetic, non-nucleosidic drug candidate. J Biol Chem 277:15566-15572.
35. Perry PJ, Gowan SM, Reszka AP, Polucci P, Jenkins TC, Kelland LR, and Neidle S (1998) 1,4- and 2,6-disubstituted amidoanthracene-9,10-dione derivatives as inhibitors of human telomerase. J Med Chem 41:3253-3260.
36. Perry PJ, Read MA, Davies RT, Gowan SM, Reszka AP, Wood AA, Kelland LR, and Neidle S (1999) 2,7-Disubstituted amidofluorenone derivatives as inhibitors of human telomerase. J Med Chem 42:2679-2684.
37. Pitts AE and Corey DR (1998) Inhibition of human telomerase by 2′-O-methyl-RNA. Proc Natl Acad Sci USA 95:11549-11554.
38. Shay JW and Bacchetti SA (1997) Survey of telomerase activity in human cancer. Eur J Cancer 33:777-791.
39. Strahl C and Blackburn EH (1996) Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines. Mol Cell Biol 16:53-65.
40. Traxler PM, Wacker O, Bach HL, Geissler JF, Kump W, Meyer T, Regenass U, Roesel JL, and Lydon N (1991) Sulfonylbenzoyl-nitrostyrenes: potential bisubstrate type inhibitors of the EGF-receptor tyrosine protein kinase. J Med Chem 34:2328-2337.
41. Vaziri H and Benchimol S (1998) Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Curr Biol 8:279-282.
42. White LK, Wright WE, and Shay JW (2001) Telomerase inhibitors. Trends Biotechnol 19:114-120.
43. Zhang X, Mar V, Zhou W, Harrington L, and Robinson MO (1999) Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev 13:2388-2399.